450 related articles for article (PubMed ID: 35657320)
21. Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M
Clin Colorectal Cancer; 2018 Sep; 17(3):e549-e555. PubMed ID: 29861156
[TBL] [Abstract][Full Text] [Related]
22. Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer.
Olivier T; Haslam A; Prasad V
BMC Med; 2023 Sep; 21(1):344. PubMed ID: 37679732
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
[TBL] [Abstract][Full Text] [Related]
24. Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study.
van den Berg I; van de Weerd S; Roodhart JML; Vink GR; van den Braak RRJC; Jimenez CR; Elias SG; van Vliet D; Koelink M; Hong E; van Grevenstein WMU; van Oijen MGH; Beets-Tan RGH; van Krieken JHJM; IJzermans JNM; Medema JP; Koopman M;
BMC Cancer; 2020 Aug; 20(1):776. PubMed ID: 32811457
[TBL] [Abstract][Full Text] [Related]
25. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
27. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.
Merk C; Martling A; Lindberg J; Benhaim L; Taieb J; Lind P
Acta Oncol; 2022 Apr; 61(4):523-530. PubMed ID: 35139729
[TBL] [Abstract][Full Text] [Related]
29. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
30. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
[TBL] [Abstract][Full Text] [Related]
31. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
32. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
Yamazaki K; Yamanaka T; Shiozawa M; Manaka D; Kotaka M; Gamoh M; Shiomi A; Makiyama A; Munemoto Y; Rikiyama T; Fukunaga M; Ueki T; Shitara K; Shinkai H; Tanida N; Oki E; Sunami E; Ohtsu A; Maehara Y; Yoshino T
Ann Oncol; 2021 Jan; 32(1):77-84. PubMed ID: 33121997
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
Park YS; Ji J; Zalcberg JR; El-Serafi M; Buzaid A; Ghosn M
Asia Pac J Clin Oncol; 2015 Dec; 11(4):334-42. PubMed ID: 26471890
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a
Taieb J; Taly V; Henriques J; Bourreau C; Mineur L; Bennouna J; Desrame J; Louvet C; Lepere C; Mabro M; Egreteau J; Bouche O; Mulot C; Hormigos K; Chaba K; Mazard T; de Gramont A; Vernerey D; André T; Laurent-Puig P
Clin Cancer Res; 2021 Oct; 27(20):5638-5646. PubMed ID: 34083233
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study).
Chen Y; Zhang J; Han G; Tang J; Guo F; Li W; Xie L; Xu H; Zhang X; Tian Y; Pan L; Shu Y; Ma L; Chen X
Front Immunol; 2023; 14():1232858. PubMed ID: 38022553
[TBL] [Abstract][Full Text] [Related]
38. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
[TBL] [Abstract][Full Text] [Related]
39. Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years.
Taha HF; Harb OA; Gertallah LM; Abdelaziz LA
J Gastrointest Cancer; 2022 Sep; 53(3):581-591. PubMed ID: 34282542
[TBL] [Abstract][Full Text] [Related]
40. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
